Patrick Therasse
Overview
Explore the profile of Patrick Therasse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
4270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dizier B, Callegaro A, Debois M, Dreno B, Hersey P, Gogas H, et al.
Clin Cancer Res
. 2019 Nov;
26(7):1725-1735.
PMID: 31732522
Purpose: Immune components of the tumor microenvironment (TME) have been associated with disease outcome. We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma...
2.
Litiere S, Isaac G, de Vries E, Bogaerts J, Chen A, Dancey J, et al.
J Clin Oncol
. 2019 Mar;
37(13):1102-1110.
PMID: 30860949
Purpose: The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with...
3.
Dreno B, Thompson J, Smithers B, Santinami M, Jouary T, Gutzmer R, et al.
Lancet Oncol
. 2018 Jun;
19(7):916-929.
PMID: 29908991
Background: Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in...
4.
Therasse P, Perron B, Novack S, Abastado J
Future Oncol
. 2017 Apr;
13(17):1527-1536.
PMID: 28427281
Cancer is a complex, multifactorial disease that for years has been the focus of intensive research efforts to explore both the molecular and biological mechanisms involved and the development of...
5.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz L, Mandrekar S, et al.
Lancet Oncol
. 2017 Mar;
18(3):e143-e152.
PMID: 28271869
Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about...
6.
Schwartz L, Seymour L, Litiere S, Ford R, Gwyther S, Mandrekar S, et al.
Eur J Cancer
. 2016 May;
62:138-45.
PMID: 27237360
Radiologic imaging of disease sites plays a pivotal role in the management of patients with cancer. Response Evaluation Criteria in Solid Tumours (RECIST), introduced in 2000, and modified in 2009,...
7.
Schwartz L, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al.
Eur J Cancer
. 2016 May;
62:132-7.
PMID: 27189322
The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were...
8.
Vansteenkiste J, Cho B, Vanakesa T, De Pas T, Zielinski M, Kim M, et al.
Lancet Oncol
. 2016 May;
17(6):822-835.
PMID: 27132212
Background: Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made...
9.
10.
Lerut E, van Poppel H, Joniau S, Gruselle O, Coche T, Therasse P
Int J Clin Exp Pathol
. 2015 Oct;
8(8):9522-32.
PMID: 26464715
Introduction: Antigen-specific active immunotherapy is an investigational therapeutic approach of potential interest for bladder cancer regardless of disease stage. Clinical development of antigen-specific immunotherapeutics against bladder cancer must be preceded...